by Brandon Roberts, Debbie Cenziper, Megan Rose and Irena Hwang

We are still reporting. If you are a current or former FDA employee or someone in the industry with information about the agency, the safety of generic drugs, or the manufacturers that make them, our team wants to hear from you. Megan Rose can be reached on Signal or WhatsApp at 202-805-4865. Debbie Cenziper can be reached on Signal or WhatsApp at 301-222-3133. You can also email us at FDA@propublica.org.

It’s been 17 years since tainted blood thinner from China injured or killed hundreds of people in the United States, and since then, contaminants and other defects have appeared in a cross section of America’s generic drugs.

To understand how risky drugs could end up in our medicine cabinets, ProPublica spent more than a year investigating the U.S. Food and Drug Administration’s oversight of foreign factories accused of violating critical quality standards. Reporters focused largely on factories in India, a key supplier of the world’s generic drugs.

The investigation exposed how the FDA, without warning the public, allowed more than 150 drugs or their ingredients into the United States over the past dozen years even though they were made at factories banned from shipping products here. The agency did not routinely test the drugs as they were circulating in the United States or actively track whether consumers had been harmed.

The FDA and several former agency officials told ProPublica they believed the medications that were........

© ProPublica